Kianoush Kashani1,2, Kumar Sarvottam3, Naveen L Pereira4, Erin F Barreto5,6, Cassie C Kennedy2,6,7. 1. Division of Nephrology and Hypertension, Rochester, MN, USA. 2. Division of Pulmonary and Critical Care Medicine, Rochester, MN, USA. 3. Internal Medicine Residency Program, Sinai Hospital of Baltimore, Baltimore, MD, USA. 4. Department of Cardiovascular Medicine, Rochester, MN, USA. 5. Pharmacy Services, Rochester, MN, USA. 6. Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Rochester, MN, USA. 7. Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Rochester, MN, USA.
Abstract
BACKGROUND: Frailty, including low muscle mass, is an emerging risk factor for poor outcomes after lung transplant. The sarcopenia index (SI)-(serum creatinine value/cystatin C value) × 100-is a novel blood test to approximate muscle mass. We sought to validate SI among lung transplant patients. METHODS: We retrospectively identified adult lung transplant recipients from 2000 through 2012 at our institution who underwent computed tomography within 1 year before transplant and had preserved blood samples. Creatinine and cystatin C values were measured using the samples and used to calculate SI. Muscle mass was estimated by computed tomographic measurement of skeletal muscle cross-sectional surface area (SA) at the L1 to L3 vertebral levels. Correlation between SI and SA was evaluated. RESULTS: Of 28 patients meeting eligibility criteria, most were white (96%) and men (54%). Median (interquartile range) body mass index, SI, and SA were 25.9 (22-30) kg/m2 , 106 (91-119), and 157 (113-195) cm2, respectively. The Pearson correlation coefficient between SI and SA was significant at L2 (0.43; P = .02) and L3 (0.41; P = .03). CONCLUSION: Sarcopenia index is a potentially objective measure for estimating muscle mass that is noninvasive and less expensive. Sarcopenia index could be considered in lung transplant candidate selection following prospective validation in larger cohorts.
BACKGROUND: Frailty, including low muscle mass, is an emerging risk factor for poor outcomes after lung transplant. The sarcopenia index (SI)-(serum creatinine value/cystatin C value) × 100-is a novel blood test to approximate muscle mass. We sought to validate SI among lung transplant patients. METHODS: We retrospectively identified adult lung transplant recipients from 2000 through 2012 at our institution who underwent computed tomography within 1 year before transplant and had preserved blood samples. Creatinine and cystatin C values were measured using the samples and used to calculate SI. Muscle mass was estimated by computed tomographic measurement of skeletal muscle cross-sectional surface area (SA) at the L1 to L3 vertebral levels. Correlation between SI and SA was evaluated. RESULTS: Of 28 patients meeting eligibility criteria, most were white (96%) and men (54%). Median (interquartile range) body mass index, SI, and SA were 25.9 (22-30) kg/m2 , 106 (91-119), and 157 (113-195) cm2, respectively. The Pearson correlation coefficient between SI and SA was significant at L2 (0.43; P = .02) and L3 (0.41; P = .03). CONCLUSION:Sarcopenia index is a potentially objective measure for estimating muscle mass that is noninvasive and less expensive. Sarcopenia index could be considered in lung transplant candidate selection following prospective validation in larger cohorts.
Authors: Jason D Christie; Leah B Edwards; Anna Y Kucheryavaya; Paul Aurora; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2010-10 Impact factor: 10.247
Authors: Diana J Kelm; Sara L Bonnes; Michael D Jensen; Patrick W Eiken; Matthew A Hathcock; Walter K Kremers; Cassie C Kennedy Journal: Clin Transplant Date: 2016-02-11 Impact factor: 2.863
Authors: Kamyar Kalantar-Zadeh; Elani Streja; Csaba P Kovesdy; Antigone Oreopoulos; Nazanin Noori; Jennie Jing; Allen R Nissenson; Mahesh Krishnan; Joel D Kopple; Rajnish Mehrotra; Stefan D Anker Journal: Mayo Clin Proc Date: 2010-11 Impact factor: 7.616
Authors: J Kyhse-Andersen; C Schmidt; G Nordin; B Andersson; P Nilsson-Ehle; V Lindström; A Grubb Journal: Clin Chem Date: 1994-10 Impact factor: 8.327
Authors: Satish Chandrashekaran; Cesar A Keller; Walter K Kremers; Steve G Peters; Matthew A Hathcock; Cassie C Kennedy Journal: J Heart Lung Transplant Date: 2014-11-17 Impact factor: 10.247
Authors: Kianoush B Kashani; Erin N Frazee; Lucie Kukrálová; Kumar Sarvottam; Vitaly Herasevich; Phillip M Young; Rahul Kashyap; John C Lieske Journal: Crit Care Med Date: 2017-01 Impact factor: 7.598
Authors: C Cooper; R Fielding; M Visser; L J van Loon; Y Rolland; E Orwoll; K Reid; S Boonen; W Dere; S Epstein; B Mitlak; Y Tsouderos; A A Sayer; R Rizzoli; J Y Reginster; J A Kanis Journal: Calcif Tissue Int Date: 2013-07-11 Impact factor: 4.333
Authors: Erin F Barreto; Tejaswi Kanderi; Sara R DiCecco; Arnaldo Lopez-Ruiz; Janelle O Poyant; Kristin C Mara; Joy Heimgartner; Ognjen Gajic; Andrew D Rule; Erin M Nystrom; Kianoush B Kashani Journal: JPEN J Parenter Enteral Nutr Date: 2018-12-18 Impact factor: 4.016
Authors: Ezequiel Mauro; Juan Manuel Diaz; Lucrecia Garcia-Olveira; Juan Carlos Spina; Lorena Savluk; Fernanda Zalazar; Julia Saidman; Martin De Santibañes; Juan Pekolj; Eduardo De Santibañes; Gonzalo Crespo; Juan G Abraldes; Adrían Gadano Journal: Hepatol Commun Date: 2022-03-03
Authors: Lara Hessels; Niels Koopmans; Antonio W Gomes Neto; Meint Volbeda; Jacqueline Koeze; Annemieke Oude Lansink-Hartgring; Stephan J Bakker; Heleen M Oudemans-van Straaten; Maarten W Nijsten Journal: Intensive Care Med Date: 2018-09-07 Impact factor: 17.440